Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 11/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 6/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.39 |
| ▸ | HTT | P42858 | 4/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RGS12 | O14924 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904832 | 0.89 | HSPB1 (0.46) | HSPB1MAPTBLMALDH1A1L3MBTL1 | |
| SCHEMBL9900414 | 0.86 | MEN1 (0.35) | HSPB1MAPTALDH1A1L3MBTL1KDM4E | |
| SCHEMBL9905722 | 0.82 | HSPB1 (0.49) | HSPB1MAPTBLMALDH1A1L3MBTL1 | |
| SCHEMBL30193740 | 0.82 | HSPB1 (0.49) | HSPB1MAPTBLMALDH1A1L3MBTL1 | |
| SCHEMBL9905733 | 0.81 | KEAP1 (0.50) | ALDH1A1KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL23279398 | 0.78 | KEAP1 (0.32) | MAPTKDM4ERAB9A | |
| SCHEMBL23780536 | 0.77 | — | — | |
| SCHEMBL16650573 | 0.77 | KEAP1 (0.31) | — | |
| SCHEMBL9904958 | 0.76 | MEN1 (0.34) | HSPB1MAPTLMNAMEN1KMT2A | |
| SCHEMBL16649854 | 0.75 | HTR2C (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-02-21 | — | — | US | disclosed |
| US-11541052-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | AUTIFONY THERAPEUTICS LIMITED (GB) | 2021-12-14 | — | — | US | disclosed |
| US-20210023084-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2021-01-28 | — | — | US | disclosed |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2020-11-19 | — | — | US | disclosed |
| US-10835534-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-11-17 | — | — | US | disclosed |
| US-20200179385-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2020-06-11 | — | — | US | disclosed |
| US-10555945-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-02-11 | — | — | US | disclosed |
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | GLAXOSMITHKLINE S.P.A. (IT) | 2019-06-27 | — | — | US | disclosed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133175-B2 | Compounds | AUTIFONY THERAPEUTICS LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | disclosed |
| US-20140323508-A1 | NOVEL COMPOUNDS | AUTIFONY SRL (IT) | 2014-10-30 | — | — | US | disclosed |
| EP-2788339-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2649066-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | Autifony Therapeutics Limited (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| WO-2013083994-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2013-06-13 | — | — | WO | disclosed |
| WO-2012076877-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | AUTIFONY THERAPEUTICS LIMITED (GB) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192516-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | HSPB1 1810/4885MAPT 3926/4885BLM 2752/4885 |
| US-11583527-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | HSPB1 1810/4885MAPT 3926/4885BLM 2752/4885 |
| US-20220054490-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | HSPB1 1810/4885MAPT 3926/4885BLM 2752/4885 |
| US-10835534-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | HSPB1 2876/4885MAPT 2485/4885BLM 2452/4885 |
| US-20200360379-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNN3, KCND3, KCNA3 | HSPB1 1810/4885MAPT 3926/4885BLM 2752/4885 |
| US-10555945-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | HSPB1 2876/4885MAPT 2485/4885BLM 2452/4885 |
| US-20200179385-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | HSPB1 2481/4885MAPT 2154/4885BLM 3083/4885 |
| US-20130267510-A1 | HYDANTOIN DERIVATIVES USEFUL AS KV3 INHIBITORS | KCNA3, KCND3, KCNN3 | HSPB1 1929/4885MAPT 3971/4885BLM 3640/4885 |
| US-11197859-B2 | Hydantoin derivatives useful as Kv3 inhibitors | KCNN3, KCND3, KCNA3 | HSPB1 1810/4885MAPT 3926/4885BLM 2752/4885 |
| US-20210023084-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | HSPB1 2481/4885MAPT 2154/4885BLM 3083/4885 |
| US-20140323508-A1 | NOVEL COMPOUNDS | KCNN3, KCND3, KCNA3 | HSPB1 2481/4885MAPT 2154/4885BLM 3083/4885 |
| US-11541052-B2 | Compounds | KCNN3, KCNA3, KCNQ3 | HSPB1 2876/4885MAPT 2485/4885BLM 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.